New Antiangiogenesis Drug Shows Early Potential for Stopping Tumor Growth
A drug called VEGF Trap, which blocks the formation of blood vessels that feed tumors (a process called angiogenesis), is showing early promise for treating several types of cancer. The drug is in a new class called angiogenesis inhibitors, which also includes bevacizumab (Avastin�), recently approved by the US Food and Drug Administration for treating colorectal cancer.
VEGF (pronounced "veg-eff") is short for vascular endothelial growth factor, a protein secreted by many tumors to stimulate angiogenesis. VEGF Trap works by binding to VEGF protein circulating in the body, preventing it from attaching to its receptor. Without such receptor binding, tumors cannot form new blood vessels, which they need to grow and spread. In the laboratory, VEGF Trap appears to be more effective than bevacizumab in binding to VEGF, but it still has several hurdles to clear before it can be approved for general use in patients.
The phase I trial, led by Memorial Sloan-Kettering medical oncologist Jakob Dupont, included 38 patients with advanced solid tumors, including colorectal, ovarian, thyroid, and lung cancers. Seventeen patients � nearly half � saw no growth of their tumors for at least three months. The side effects of the drug were minimal.
The research study, which was presented at the American Society of Clinical Oncology annual meeting in June, was funded by Regeneron Pharmaceuticals, which developed VEGF Trap.
Regn is the same firm that had a drug was going to make everyone loose wt. It failed miserably on that score and the stock went from tghe 20's to single digits. Anyone who invests on p1 or p2 trials deserves to have their head handed to them. VEGF may or may not work but it will be at least 5 years before it can come to market. Only a sucker would take that bait. And if I'm not mistaken the ceo is (or was) a former head of merck. We all know now what a good job he did with them